Physician

Michael J Lipinski, MD, PHD

According to 2025 Medicare claims, Michael Lipinski, MD, PHD (NPI: 1184846289) practices internal medicine in the Charlottesville, VA market, with the plurality of this provider's patient population coming from Albemarle, VA. This provider's primary affiliated billing organization is CARDIOVASCULAR ASSOCIATES OF CHARLOTTESVILLE, PLC (NPI: 1891865622; TIN: 205577233) and primary practice location at 22911-8844.

Lipinski's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,525 traditional Medicare patients, billed 4,675 HCPCS/CPT codes, and received $312,267 in Medicare payments. The top billing code was 78452 (Nuclear medicine studies of heart muscle at rest and with stress and spect). Part D data shows 6,180 prescription claims across 672 beneficiaries totaling $732,833 in drug costs, led by Eliquis (Apixaban). 2017 DME data shows 42 claims. Open Payments data shows 17 records totaling $46,678. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $49,510 to $312,267. Similarly, Part D prescription costs have moved sharply higher in recent years, from $4,870 to $732,833. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	138	329	$49,510
2016	380	944	$135,025
2017	649	1,443	$145,455
2018	1,090	3,077	$266,175
2019	1,397	4,007	$332,293
2020	1,837	4,975	$375,934
2021	1,729	4,689	$374,311
2022	1,569	4,321	$336,042
2023	1,539	4,605	$352,195
2024	1,525	4,675	$312,267

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	17	131	$4,870
2016	26	291	$14,076
2017	29	331	$15,484
2018	141	985	$82,732
2019	266	2,063	$159,840
2020	412	3,297	$293,230
2021	493	3,956	$383,574
2022	545	4,395	$435,166
2023	597	5,110	$697,553
2024	672	6,180	$732,833

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	42	$5,439
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78452	Nuclear medicine studies of heart muscle at rest and with stress and spect	115	115	$267
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	621	625	$101
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	549	1,063	$81
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	575	932	$9
99152	Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes	156	168	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	357	19,468	$365,303
Xarelto	Rivaroxaban	65	4,410	$81,595
Jardiance	Empagliflozin	79	3,119	$59,675
Brilinta	Ticagrelor	62	3,135	$44,332
Entresto	Sacubitril/Valsartan	50	1,850	$41,263

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$46,678	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael J. Lipinski, MD, PHD?

Tedicare shows public-source Medicare data for Michael J. Lipinski, MD, PHD (NPI 1184846289), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael J. Lipinski, MD, PHD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Michael J. Lipinski, MD, PHD?

Michael J. Lipinski, MD, PHD is linked to CARDIOVASCULAR ASSOCIATES OF CHARLOTTESVILLE, PLC (billing NPI 1891865622) in the available physician profile data.

Does Michael J. Lipinski, MD, PHD have Open Payments data?

Michael J. Lipinski, MD, PHD has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.